Citizens Reiterates Market Outperform on Bicara Therapeutics, Maintains $31 Price Target

Benzinga Newsdesk www.benzinga.com Negative 87.8%

Neg 87.8% Neu 0% Pos 0%

Citizens analyst Reni J. Benjamin reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform and maintains $31 price target.